Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Diabetes

Free Subscription Articles published in BMJ Retrieve available abstracts of 72 articles: HTML format

Single Articles

January 2026
1. ALLOTEY J, Coomar D, Ensor J, Ruiz-Calvo G, et al
   Effects of lifestyle interventions in pregnancy on gestational diabetes: individual participant data and network meta-analysis.
   BMJ. 2026;392:e084159.
   PubMed     Abstract available
   
   
   December 2025
2. O'DOWD A
   Diabetes prevention: Almost a million people access NHS scheme.
   BMJ. 2025;391:r2686.
   PubMed    
   
   
   November 2025
3. LOGAN M
   Trump expands visa requirements to include diabetes and obesity.
   BMJ. 2025;391:r2400.
   PubMed    
   
   
   October 2025
4. HONG B, Lee H, Jung K, Rhee SY, et al
   Sodium-glucose cotransporter-2 inhibitors and risk of autoimmune rheumatic diseases: population based cohort study.
   BMJ. 2025;391:e085196.
   PubMed     Abstract available
   
   
   
5. TAYLOR L
   Sixty seconds on . . . type 5 diabetes.
   BMJ. 2025;391:r2092.
   PubMed    
   
   
   September 2025
6. MCCRAY BA, Stino AM, Davalos L, Quigley S, et al
   Atypical diabetic neuropathies.
   BMJ. 2025;390:e081109.
   PubMed     Abstract available
   
   
   
7. FARMER A, Patel K, Dambha-Miller H
   Once weekly insulin in type 2 diabetes.
   BMJ. 2025;390:r1931.
   PubMed    
   
   
   
8. LUCEWICZ SAMARAWICKRAMA A, Pasupathy D
   Preventing gestational diabetes.
   BMJ. 2025;390:r1900.
   PubMed    
   
   
   
9. SUJAN MJ, Skarstad HM, Rosvold G, Fougner SL, et al
   Time restricted eating and exercise training before and during pregnancy for people with increased risk of gestational diabetes: single centre randomised controlled trial (BEFORE THE BEGINNING).
   BMJ. 2025;390:e083398.
   PubMed     Abstract available
   
   
   
10. TAYLOR L
    WHO adds controversial cancer and diabetes treatments to essential medicines list.
    BMJ. 2025;390:r1881.
    PubMed    
    
    
    August 2025
11. BOWIE K
    Type 2 diabetes: SGLT-2 inhibitors to be offered as first line treatment in major guidance "shake-up".
    BMJ. 2025;390:r1777.
    PubMed    
    
    
    
12. KAR P
    Partha Kar: The Super Six diabetes care model offers lessons for shifting care into the community.
    BMJ. 2025;390:r1727.
    PubMed    
    
    
    
13. BOWIE K
    Type 1 diabetes: UK approves first drug for delaying onset.
    BMJ. 2025;390:r1762.
    PubMed    
    
    
    
14. THEODORAKI A
    Management of type 2 diabetes.
    BMJ. 2025;390:r1726.
    PubMed    
    
    
    
15. AGARWAL A, Mustafa R, Manja V, Agoritsas T, et al
    Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline.
    BMJ. 2025;390:e082071.
    PubMed     Abstract available
    
    
    
16. NONG K, Jeppesen BT, Shi Q, Agoritsas T, et al
    Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.
    BMJ. 2025;390:e083039.
    PubMed     Abstract available
    
    
    
17. MISRA A, Sattar N, Ghosh A, Nassar M, et al
    Type 2 diabetes in South Asians.
    BMJ. 2025;390:e079801.
    PubMed     Abstract available
    
    
    
18. IBSEN DB, Zhang Y
    Potatoes and risk of type 2 diabetes.
    BMJ. 2025;390:r1557.
    PubMed    
    
    
    
19. MOUSAVI SM, Gu X, Imamura F, AlEssa HB, et al
    Total and specific potato intake and risk of type 2 diabetes: results from three US cohort studies and a substitution meta-analysis of prospective cohorts.
    BMJ. 2025;390:e082121.
    PubMed     Abstract available
    
    
    July 2025
20. NOLAN T
    Diabetes deprescribing . . . and other research.
    BMJ. 2025;390:r1365.
    PubMed    
    
    
    
21. KOGA H
    Stigmatising language made me avoid diabetes care; meaningful engagement with people with diabetes is the answer.
    BMJ. 2025;390:r981.
    PubMed     Abstract available
    
    
    June 2025
22. KAR P
    Partha Kar: The spending review is an opportunity to reevaluate priorities in diabetes care.
    BMJ. 2025;389:r1175.
    PubMed    
    
    
    
23. LIN J, Huang Y, Xu B, Gu X, et al
    Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial.
    BMJ. 2025;389:e083735.
    PubMed     Abstract available
    
    
    April 2025
24. 
    Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study.
    BMJ. 2025;389:r845.
    PubMed    
    
    
    February 2025
25. SHAPIRO SB, Yin H, Yu OHY, Rej S, et al
    Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study.
    BMJ. 2025;388:e080679.
    PubMed     Abstract available
    
    
    January 2025
26. HOPE D, Valabhji J
    SGLT2 inhibitors and dietary calorie restriction for type 2 diabetes remission.
    BMJ. 2025;388:r40.
    PubMed    
    
    
    
27. LIU Y, Chen Y, Ma J, Lin J, et al
    Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.
    BMJ. 2025;388:e081820.
    PubMed     Abstract available
    
    
    December 2024
28. MOTTELSON M, Helby J, Nordestgaard BG, Ellervik C, et al
    Mortality and risk of diabetes, liver disease, and heart disease in individuals with haemochromatosis HFE C282Y homozygosity and normal concentrations of iron, transferrin saturation, or ferritin: prospective cohort study.
    BMJ. 2024;387:e079147.
    PubMed     Abstract available
    
    
    
29. LIU B, Zong G, Zhu L, Hu Y, et al
    Chocolate intake and risk of type 2 diabetes: prospective cohort studies.
    BMJ. 2024;387:e078386.
    PubMed     Abstract available
    
    
    November 2024
30. IACOBUCCI G
    Diabetes: Global treatment gap is widening, study finds.
    BMJ. 2024;387:q2515.
    PubMed    
    
    
    
31. SCIVIER M
    Quality care is needed for older people with diabetes in care homes-now and for the future.
    BMJ. 2024;387:q2471.
    PubMed    
    
    
    
32. SVANSTROM H, Mkoma GF, Hviid A, Pasternak B, et al
    SGLT-2 inhibitors and mortality among patients with heart failure with reduced ejection fraction: linked database study.
    BMJ. 2024;387:e080925.
    PubMed     Abstract available
    
    
    October 2024
33. MCCORMICK N, Yokose C, Lu N, Wexler DJ, et al
    Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies.
    BMJ. 2024;387:e080035.
    PubMed     Abstract available
    
    
    
34. ALKABBANI W, Suissa K, Gu KD, Cromer SJ, et al
    Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study.
    BMJ. 2024;387:e080340.
    PubMed     Abstract available
    
    
    
35. MENG LC, van Gelder MMHJ, Chuang HM, Chen LK, et al
    Paternal metformin use and risk of congenital malformations in offspring in Norway and Taiwan: population based, cross national cohort study.
    BMJ. 2024;387:e080127.
    PubMed     Abstract available
    
    
    
36. LIU L, Ke W, Li H, Li F, et al
    Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial.
    BMJ. 2024;387:e080122.
    PubMed     Abstract available
    
    
    
37. AGARWAL A, Zeng X, Li S, Rayner D, et al
    Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease: a clinical practice guideline.
    BMJ. 2024;387:e080257.
    PubMed     Abstract available
    
    
    September 2024
38. WISE J
    Diabetes: Once weekly insulin could be as effective as daily injections, studies indicate.
    BMJ. 2024;386:q2005.
    PubMed    
    
    
    
39. 
    Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study.
    BMJ. 2024;386:q1911.
    PubMed    
    
    
    August 2024
40. TU SY, Shao SC, Loh CH, Huang HK, et al
    SGLT-2 inhibitors and dementia.
    BMJ. 2024;386:q1841.
    PubMed    
    
    
    
41. MAHASE E
    Semaglutide's CVD indication could cost US Medicare $145bn extra a year.
    BMJ. 2024;386:q1878.
    PubMed    
    
    
    
42. SHIN A, Koo BK, Lee JY, Kang EH, et al
    Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study.
    BMJ. 2024;386:e079475.
    PubMed     Abstract available
    
    
    
43. KMIETOWICZ Z
    SGLT-2 inhibitors for diabetes may help prevent dementia, study finds.
    BMJ. 2024;386:q1875.
    PubMed    
    
    
    
44. MAHASE E
    Diabetes: One in 10 patients on NHS's "soups and shakes" diet plan went into remission.
    BMJ. 2024;386:q1733.
    PubMed    
    
    
    July 2024
45. MAHASE E
    Semaglutide: FDA publishes warning amid reports of patients overdosing.
    BMJ. 2024;386:q1696.
    PubMed    
    
    
    
46. IACOBUCCI G
    Semaglutide: UK regulator approves drug for prevention of cardiovascular events.
    BMJ. 2024;386:q1660.
    PubMed    
    
    
    
47. MAHASE E
    GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment.
    BMJ. 2024;386:q1645.
    PubMed    
    
    
    
48. LAL N
    India: Doctors report surge in use of off label GLP-1 agonists among rich.
    BMJ. 2024;386:q1605.
    PubMed    
    
    
    
49. DYER C
    People with type 1 diabetes and disordered eating need joined-up care, says coroner after woman's death.
    BMJ. 2024;386:q1597.
    PubMed    
    
    
    
50. VANDERPANT N, Ward E, Farrell E, Theodoraki A, et al
    Insulin for people with type 2 diabetes mellitus.
    BMJ. 2024;386:e078015.
    PubMed    
    
    
    
51. WISE J
    Covid-19: Progression to clinical type 1 diabetes accelerated after infection, study suggests.
    BMJ. 2024;386:q1557.
    PubMed    
    
    
    
52. SETHI J
    Use of language in diabetes: what's in a name?
    BMJ. 2024;386:q1446.
    PubMed    
    
    
    June 2024
53. MAHASE E
    GLP-1 shortages will not resolve this year, EMA warns, amid concern over off-label use.
    BMJ. 2024;385:q1448.
    PubMed    
    
    
    
54. FU EL, Wexler DJ, Cromer SJ, Bykov K, et al
    SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.
    BMJ. 2024;385:e078483.
    PubMed     Abstract available
    
    
    
55. DOBLE E, Farrow D
    We need to tackle the increasing mountain of wasted plastic and cardboard from diabetes technologies.
    BMJ. 2024;385:q1337.
    PubMed    
    
    
    
56. ZHANG J, Li Y
    Increasing prevalence of type 1 diabetes in older age may be a good sign.
    BMJ. 2024;385:q1322.
    PubMed    
    
    
    
57. YANG K, Yang X, Jin C, Ding S, et al
    Global burden of type 1 diabetes in adults aged 65 years and older, 1990-2019: population based study.
    BMJ. 2024;385:e078432.
    PubMed     Abstract available
    
    
    
58. 
    New advances in type 1 diabetes.
    BMJ. 2024;385:q1224.
    PubMed    
    
    
    May 2024
59. JENKINS AJ, Ogle GD, Scibilia R, Schwarz P, et al
    People who need insulin are particularly vulnerable in disasters and conflicts.
    BMJ. 2024;385:q1109.
    PubMed    
    
    
    
60. BIDULKA P, Lugo-Palacios DG, Carroll O, O'Neill S, et al
    Comparative effectiveness of second line oral antidiabetic treatments among people with type 2 diabetes mellitus: emulation of a target trial using routinely collected health data.
    BMJ. 2024;385:e077097.
    PubMed     Abstract available
    
    
    April 2024
61. MAHASE E
    Diabetes UK defends partnership with Slimming World in face of criticism.
    BMJ. 2024;385:q962.
    PubMed    
    
    
    
62. SIMMS-WILLIAMS N, Treves N, Yin H, Lu S, et al
    Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
    BMJ. 2024;385:e078242.
    PubMed     Abstract available
    
    
    
63. NOLAN T
    The use of continuous glucose monitoring devices in non-diabetic adults ... and other research.
    BMJ. 2024;385:q859.
    PubMed    
    
    
    
64. SETHI J
    Breaking free from the stigma of diabetes.
    BMJ. 2024;385:q890.
    PubMed    
    
    
    
65. BOKINNI Y
    Barbados is in the grip of a diabetic foot amputation crisis.
    BMJ. 2024;385:q350.
    PubMed    
    
    
    
66. PASTERNAK B, Wintzell V, Hviid A, Eliasson B, et al
    Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
    BMJ. 2024;385:e078225.
    PubMed     Abstract available
    
    
    March 2024
67. CHRISTIE B
    Charity calls for Scottish government to increase access to diabetes technology.
    BMJ. 2024;384:q755.
    PubMed    
    
    
    
68. MAHASE E
    Type 1 diabetes: Randox removes adverts after claims that it was using fear to sell genetic test.
    BMJ. 2024;384:q744.
    PubMed    
    
    
    
69. SAUL H, Deeney B, Swaithes L, Hounkpatin H, et al
    Even short periods of diabetes remission are linked to lower risk of heart attack and stroke.
    BMJ. 2024;384:q516.
    PubMed     Abstract available
    
    
    
70. TANNE JH
    FDA approves first over-the-counter blood glucose monitor for diabetes.
    BMJ. 2024;384:q611.
    PubMed    
    
    
    
71. TANNE JH
    US food manufacturer can say that eating yogurt reduces risk of type 2 diabetes, says FDA.
    BMJ. 2024;384:q569.
    PubMed    
    
    
    February 2024
72. LANE MM, Gamage E, Du S, Ashtree DN, et al
    Ultra-processed food exposure and adverse health outcomes: umbrella review of epidemiological meta-analyses.
    BMJ. 2024;384:e077310.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Diabetes is free of charge.